Dyne Therapeutics (NASDAQ:DYN) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Dyne Therapeutics (NASDAQ:DYN) posted its quarterly earnings data on Monday. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02, Zacks reports.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN traded up $0.57 during midday trading on Tuesday, reaching $43.64. 962,248 shares of the stock traded hands, compared to its average volume of 1,591,091. The company’s 50 day moving average is $37.89 and its 200 day moving average is $30.32. Dyne Therapeutics has a one year low of $6.40 and a one year high of $45.46. The stock has a market capitalization of $3.81 billion, a PE ratio of -10.77 and a beta of 1.07.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,705 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $28.27, for a total value of $76,470.35. Following the completion of the transaction, the insider now owns 149,647 shares of the company’s stock, valued at approximately $4,230,520.69. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, COO Susanna Gatti High sold 2,738 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $28.27, for a total value of $77,403.26. Following the completion of the sale, the chief operating officer now owns 154,062 shares in the company, valued at approximately $4,355,332.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Oxana Beskrovnaya sold 2,705 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $28.27, for a total transaction of $76,470.35. Following the transaction, the insider now owns 149,647 shares in the company, valued at $4,230,520.69. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 202,133 shares of company stock worth $6,500,387. Insiders own 20.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Jefferies Financial Group raised their target price on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, May 20th. Chardan Capital raised their price objective on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, May 21st. Oppenheimer reaffirmed an “outperform” rating and issued a $47.00 target price on shares of Dyne Therapeutics in a report on Monday, May 6th. Morgan Stanley assumed coverage on Dyne Therapeutics in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price objective on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and an average target price of $46.56.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.